Evaluation of Minimal Optimal Dose of Intravenous Ferric Carboxymaltose for Treatment of Iron Deficiency Anemia and Risk of Transient Hyperferritinemia
Ahmad A Alharbi,1,2 Abdullah A Alharbi,2,3 Dhafer Salem Bashen,2 Tarek Owaidah4 1Pathology Department, College of Medicine, Majmaah University, Al Majmaah 11952, Riyadh, Kingdom of Saudi Arabia; 2Laboratory Department, Dr. Sulaiman Al-Habib Hospital in Al Takhassusi, Riyadh, Kingdom of Saudi Arabia;...
Main Authors: | Alharbi AA, Bashen DS, Owaidah T |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2022-11-01
|
Series: | Journal of Blood Medicine |
Subjects: | |
Online Access: | https://www.dovepress.com/evaluation-of-minimal-optimal-dose-of-intravenous-ferric-carboxymaltos-peer-reviewed-fulltext-article-JBM |
Similar Items
-
Incidence of Hypophosphatemia after Ferric Carboxymaltose Treatment: Single Center Experience
by: Esra TERZİ DEMİRSOY
Published: (2021-08-01) -
Randomized controlled trial to compare injection ferric carboxymaltose and oral iron in reducing postpartum anemia: A multicenter, pilot study
by: Sushil Chawla, et al.
Published: (2022-01-01) -
Symptomatic severe hypophosphatemia after intravenous ferric carboxymaltose
by: Wendy Fang, et al.
Published: (2019-10-01) -
Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose—the randomized controlled HOMe aFers study
by: I. E. Emrich, et al.
Published: (2020-07-01) -
Hypophoshatemia Incidence in Patients with Chronic Kidney Disease Treated with Intravenous Ferric Carboxymaltose and Factors Related to Hypophosphatemia
by: Abdullah Şumnu, et al.
Published: (2020-09-01)